ChromaDex(US:CDXC)2022-03-09 22:08Financial Performance - Total net sales for Q4 2021 were $178 million, a 15% increase year-over-year and a 3% increase compared to Q3 2021[51] - Tru Niagen® net sales reached $141 million in Q4 2021, representing a 14% year-over-year growth, but a 5% sequential decline compared to Q3 2021[51] - The company maintained a strong gross margin of 612% in Q4 2021, slightly up from 611% in Q3 2021 and 610% in Q4 2020[51,37] - The net loss for Q4 2021 was $(53) million, or $(008) per share, compared to a net loss of $(61) million, or $(010) per share, in Q4 2020[51] - Adjusted EBITDA, excluding total legal expense, showed a loss of $(18) million in Q4 2021, compared to a loss of $(11) million in Q4 2020[51] - Full year 2021 net sales reached $67449 million, a 14% increase compared to 2020[46] Sales Mix - E-commerce accounted for 63% of net sales in Q4 2020 and 61% in Q4 2021[23] - Niagen® ingredient sales represented 14% of net sales in both Q4 2020 and Q4 2021[23] - Tru Niagen® net sales accounted for 79% of total net sales in Q4 2021, compared to 85% in Q3 2021[23] - Niagen®-related net sales made up 94% of total net sales in Q4 2021, slightly down from 95% in Q3 2021[23] Expenses - Selling and marketing expenses accounted for 487% of net sales in Q4 2021, compared to 409% in Q4 2020 and 417% in Q3 2021[51,37] - General and administrative expenses were $65 million in Q4 2021, a decrease of $(47) million sequentially and $(18) million year-over-year, primarily due to lower legal expenses[51]